# Methylene Blue vs Cyanokit for Intraoperative Vasoplegic Syndrome in Liver Transplant Patients

> **NCT04054999** · PHASE4 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 19 (actual)

## Conditions studied

- Vasoplegic Syndrome
- Liver Transplant; Complications

## Interventions

- **DRUG:** Hydroxocobalamin
- **DRUG:** Methylene Blue

## Key facts

- **NCT ID:** NCT04054999
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-30
- **Primary completion:** 2023-02-27
- **Final completion:** 2024-02-27
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2024-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04054999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04054999, "Methylene Blue vs Cyanokit for Intraoperative Vasoplegic Syndrome in Liver Transplant Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04054999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*